Abiomed (ABMD) Announces Publication of Protect II Cost Effectiveness Study in American Health & Drug Benefits Journal
5/1/2013 11:47:21 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
DANVERS, Mass., May 1, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced the publication of the PROTECT II Cost Effectiveness Study in the American Health & Drug Benefits (AHDB) journal, titled "A Value-Based Analysis of Hemodynamic Support Strategies for High-Risk Heart Failure Patients Undergoing a Percutaneous Coronary Intervention."
Help employers find you! Check out all the jobs and post your resume.
comments powered by